Vizsgálati helyszín
Synexus Polska Sp. z o.o.
Wroclaw, 50-381, LengyelországEU-13 felzárkózó országMég nincs intézményhez kötve
- 21futó vizsgálat
- 18lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 39 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis26 vizsgálat
- 2. fázis12 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Lezárult18 vizsgálat
- Fut, nem toboroz14 vizsgálat
- Toboroz6 vizsgálat
- Még nem toboroz1 vizsgálat
- Fő szponzor
- Pfizer4 vizsgálat
- Akero Therapeutics Inc.2 vizsgálat
- Alumis Inc2 vizsgálat
- Ascletis Pharma (China) Co. Ltd.2 vizsgálat
- AstraZeneca2 vizsgálat
- és még 25
Futó vizsgálatok
Toboroz
Efficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Weight-Related Comorbidities
2026-526172-23-00· 3. fázis· Ascletis Pharma (China) Co. Ltd.· Forrás
Toboroz
Efficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Type 2 Diabetes Mellitus
2026-526336-39-00· 3. fázis· Ascletis Pharma (China) Co. Ltd.· Forrás
Még nem toboroz
A study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis
2026-526184-38-00· 2. fázis· Enveda Therapeutics Inc.· Forrás
Fut, nem toboroz
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of CX11 Tablets in Patients with Type 2 Diabetes Mellitus
2025-524514-28-00· 2. fázis· Corxel Pharmaceuticals Inc.· Forrás
Fut, nem toboroz
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
NCT07400653· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
NCT07311850· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
NCT07217015· 2. fázis· Kymera Therapeutics, Inc.· Forrás
Toboroz
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498· 3. fázis· Incyte Corporation· Forrás
Toboroz
Clinical trial to investigate the efficacy and tolerability of Lipovir® Gel (Acyclovir 5%) compared to Zovirax® Cream (Acyclovir 5%) and placebo on patients with recurrent herpes labialis
2023-510338-10-00· 3. fázis· Laboratorios Ojer Pharma S.L.· Forrás
Fut, nem toboroz
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541· 3. fázis· Alumis Inc· Forrás
Toboroz
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
2024-512895-36-00· 3. fázis· Akero Therapeutics Inc.· Forrás
Toboroz
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883· 2. fázis· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Forrás
Fut, nem toboroz
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873· 3. fázis· AstraZeneca· Forrás
Toboroz
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
2023-505141-48-00· 3. fázis· Akero Therapeutics Inc.· Forrás
Fut, nem toboroz
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
NCT06113471· 3. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT06136741· 2. fázis· Nektar Therapeutics· Forrás
Fut, nem toboroz
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
NCT05995964· 2. fázis· Pfizer· Forrás
Fut, nem toboroz
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578· 2/3. fázis· Sanofi· Forrás
Fut, nem toboroz
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728· 3. fázis· Inventiva Pharma· Forrás
Fut, nem toboroz
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
NCT04908202· 3. fázis· Bristol-Myers Squibb· Forrás
Fut, nem toboroz
A clinical trial to evaluate the safety and effectiveness of MGL-3196 (resmetirom) in patients with Non-Alcoholic Steatohepatitis (NASH) and reduce progression of liver damage and resolve NASH
2024-510626-89-00· 3. fázis· Madrigal Pharmaceuticals Inc.· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A trial to find the effect of Ginkgo biloba extract EGb 761® and how safe it is in participants with cognitive impairment associated with post COVID-19 syndrome
2024-517199-39-00· 2. fázis· Dr. Willmar Schwabe GmbH & Co. KG· Forrás
Lezárult
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
NCT06664619· 3. fázis· Teva Branded Pharmaceutical Products R&D LLC· Forrás
Lezárult
A Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia® Sourced from the European Union in Postmenopausal Women with Osteoporosis
2024-512417-41-00· 3. fázis· Xentria Inc.· Forrás
Lezárult
A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT06602219· 2. fázis· DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company· Forrás
Lezárult
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
NCT06586112· 3. fázis· Alumis Inc· Forrás
Lezárult
Efficacy, safety, PK, PD, and immunogenicity of BP16 in post-menopausal osteoporosis
2023-503790-37-00· 3. fázis· Curateq Biologics Private Limited· Forrás
Lezárult
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
NCT06077864· 3. fázis· Boehringer Ingelheim· Forrás
Lezárult
A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus
NCT05856448· 2. fázis· Lakefront Biotherapeutics NV· Forrás
Lezárult
Comparative efficacy, safety, pharmacokinetic, and immunogenicity study of LY06006 and EU-Prolia in postmenopausal women with osteoporosis
NCT05853354· 3. fázis· Shandong Boan Biotechnology Co. Ltd.· Forrás
Lezárult
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
NCT05595642· 3. fázis· Hoffmann-La Roche· Forrás
Lezárult
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
NCT04991935· 3. fázis· Celgene· Forrás
Lezárult
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma
NCT05251259· 2. fázis· AstraZeneca· Forrás
Lezárult
To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis
NCT04684485· 2. fázis· Sun Pharmaceutical Industries Limited· Forrás
Lezárult
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
NCT03989206· 3. fázis· Galderma R&D· Forrás
Lezárult
Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus
NCT03920267· 2. fázis· Bristol-Myers Squibb· Forrás
Lezárult
Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease
2024-511553-22-00· 3. fázis· Celgene International II SARL· Forrás
Lezárult
Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn's Disease
2023-510426-33-00· 3. fázis· Celgene International II S.a.r.l.· Forrás
Lezárult
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT03422822· 3. fázis· Pfizer· Forrás
Hibát jelzek